Extracorporeal cell therapy of septic shock patients with donor granulocytes: A pilot study

Critical Care

Volumn 15, Issue 2, 2011, Pages

  Altrichter, Jens ^a   Sauer, Martin ^a   Kaftan, Katharina ^a   Birken, Thomas ^a   Gloger, Doris ^a   Gloger, Martin ^a   Henschel, Jörg ^a   Hickstein, Heiko ^a   Klar, Ernst ^a   Koball, Sebastian ^a   Pertschy, Annette ^a   Nöldge Schomburg, Gabriele ^a   Vagts, Dierk A ^a   Mitzner, Steffen R ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTOXIN; HLA DR ANTIGEN; NORADRENALIN; PROCALCITONIN; UREA;

ADULT; APACHE; ARTICLE; BIOREACTOR; CELL THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; EXTRACORPOREAL CELL THERAPY; FEMALE; GRANULOCYTE; HUMAN; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; MALE; MEAN ARTERIAL PRESSURE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; TREATMENT OUTCOME; AGED; FOLLOW UP; INTENSIVE CARE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TRANSPLANTATION;

AGED; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 79952103103     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10076     Document Type: Article

References (41)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
2. Karzai W, Cui X, Heinicke N, Niemann C, Gerstenberger EP, Correa R, Banks S, Mehlhorn B, Bloos F, Reinhart K, Eichacker. Neutrophil stimulation with granulocyte colony-stimulating factor worsens ventilator-induced lung injury and mortality in rats. Anesthesiology 2005, 103:996-1005. 10.1097/00000542-200511000-00014, 16249674.
3. Hoesel LM, Neff TA, Neff SB, Younger JG, Olle EW, Gao H, Pianko MJ, Bernacki KD, Sarma JV, Ward PA. Harmful and protective roles of neutrophils in sepsis. Shock 2005, 24:40-47. 10.1097/01.shk.0000170353.80318.d5, 15988319.
4. Scholz M, Cinatl J, Schädel-Höpfner M, Windolf J. Neutrophils and the blood-brain barrier dysfunction after trauma. Med Res Rev 2007, 27:401-416. 10.1002/med.20064, 16758487.
5. Alves-Filho JC, de Freitas A, Spiller F, Souto FO, Cunha FQ. The role of neutrophils in severe sepsis. Shock 2008, 30:3-9. 10.1097/SHK.0b013e3181818466, 18704017.
6. Caille V, Chiche JD, Nciri N, Berton C, Gibot S, Boval B, Payen D, Mira JP, Mebazaa A. Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock 2004, 22:521-526. 10.1097/01.shk.0000143410.63698.57, 15545822.
7. Kaufmann I, Hoelzl A, Schliephake F, Hummel T, Chouker A, Peter K, Thiel M. Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity. Shock 2006, 26:254-261. 10.1097/01.shk.0000223131.64512.7a, 16912650.
8. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003, CD003066.
9. Napolitano LM. Immune stimulation in sepsis: to be or not to be?. Chest 2005, 127:1882-1885. 10.1378/chest.127.6.1882, 15947295.
10. Murphey ED, Sherwood ER. Bacterial clearance and mortality are not improved by a combination of IL-10 neutralization and IFN-gamma administration in a murine model of post-CLP immunosuppression. Shock 2006, 26:417-424. 10.1097/01.shk.0000226343.70904.4f, 16980891.
11. Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev 2003, CD003956.
12. Stanworth SJ, Massey E, Hyde C, Brunskill S, Lucas G, Navarrete C, Marks DI. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2005, CD005339.
13. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, Freireich EJ, Raad II. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004, 101:2859-2865. 10.1002/cncr.20710, 15529309.
14. Mitzner SR, Freytag J, Sauer M, Kleinfeldt T, Altrichter J, Klöhr S, Koball S, Stange J, Ringel B, Nebe B, Schmidt H, Podbielski A, Noeldge-Schomburg G, Schmidt R. Use of human preconditioned phagocytes for extracorporeal immune support: introduction of a concept. Ther Apher 2001, 5:423-432. 10.1046/j.1526-0968.2001.00378.x, 11778929.
15. Sauer M, Altrichter A, Kreutzer HJ, Lögters T, Scholz M, Nöldge-Schomburg G, Schmidt R, Mitzner SR. Extracorporeal cell therapy with granulocytes in a pig-model of Gram-positive sepsis. Crit Care Med 2009, 37:606-613. 10.1097/CCM.0b013e318194aa77, 19114920.
16. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
17. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
19. Lemeshow S, Le Gall JR. Modeling the severity of illness of ICU patients. A systems update. JAMA 1994, 272:1049-1055. 10.1001/jama.272.13.1049, 8089888.
20. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. (Erratum in: JAMA 1994, 271:1321), 10.1001/jama.270.24.2957, 8254858.
21. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008, 34:17-60. 10.1007/s00134-007-0934-2, 2249616, 18058085.
22. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007, 35:2677-2685. 10.1097/01.CCM.0000295263.12774.97, 18074464.
23. Bochud PY, Calandra T. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003, 326:262-266. 10.1136/bmj.326.7383.262, 1125122, 12560281.
24. Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest 2003, 123:451S-459S. 10.1378/chest.123.5_suppl.451S, 12740228.
25. Ronco C, Inguaggiato P, D'Intini V, Cole L, Bellomo R, Poulin S, Bordoni V, Crepaldi C, Gastaldon F, Brendolan A, Trairak P, Khajohn T. The role of extracorporeal therapies in sepsis. J Nephrol 2003, 16:S34-S41.
26. Honore PM, Joannes-Boyau O, Boer W, Collin V. High-volume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif 2009, 28:1-11. 10.1159/000210031, 19325233.
27. Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C, Krieg H, Wegner B, Bellomo R, Neumayer HH. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006, 34:2099-2104. 10.1097/01.CCM.0000229147.50592.F9, 16763508.
28. Rimmelé T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, Goudable J, Etienne J, Chassard D, Bricca G, Allaouchiche B. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009, 24:421-427.
29. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002, 30:1250-1255. 10.1097/00003246-200206000-00015, 12072677.
30. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004, 32:801-805. 10.1097/01.CCM.0000114997.39857.69, 15090965.
31. Bellomo R, Honoré PM, Matson J, Ronco C, Winchester J. Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs 2005, 28:450-458.
32. Peng Z, Singbartl K, Simon P, Rimmelé T, Bishop J, Clermont G, Kellum JA. Blood purification in sepsis: a new paradigm. Contrib Nephrol 2010, 165:322-328. full_text, 20427984.
33. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002, 28:1434-1439. 10.1007/s00134-002-1410-7, 12373468.
34. Demetriou AA, Brown RS, Busuttil RW, Fair J, McGuire BM, Rosenthal P, Am Esch JS, Lerut J, Nyberg SL, Salizzoni M, Fagan EA, de Hemptinne B, Broelsch CE, Muraca M, Salmeron JM, Rabkin JM, Metselaar HJ, Pratt D, De La Mata M, McChesney LP, Everson GT, Lavin PT, Stevens AC, Pitkin Z, Solomon BA. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004, 239:660-667. 10.1097/01.sla.0000124298.74199.e5, 1356274, 15082970.
35. Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, Szerlip HM, Ye J, Paganini EP, Dworkin L, Finkel KW, Kraus MA, Humes HD. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008, 19:1034-1040. 10.1681/ASN.2007080895, 2386731, 18272842.
36. Stange J, Mitzner S. Cell sources for bioartificial liver support. Int J Artif Organs 1996, 19:14-17.
37. Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K, Cappadoro C, Fu M, Plisco MS, Sadaka FG, Veremakis C. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006, 34:2302-2308. 10.1097/01.CCM.0000234034.51040.7F, 16849995.
38. Blajchman MA. The clinical benefits of the leukoreduction of blood products. J Traum 2006, 60:S83-S90. 10.1097/01.ta.0000199537.09201.7b, 16763486.
39. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007, 33:1563-1570. 10.1007/s00134-007-0754-4, 17594074.
40. Dünser MW, Ruokonen E, Pettilä V, Ulmer H, Torgersen C, Schmittinger CA, Jakob S, Takala J. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009, 13:R181. 2811945, 19917106.
41. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver support - comparison of different methods. Therapeutic Apheresis and Dialysis 2006, 10:108-117. 10.1111/j.1744-9987.2006.00351.x, 16684211.